ImmunityBio Expands ANKTIVA to Saudi Arabia Amid Persistent Financial and Regulatory Headwinds

What happened

ImmunityBio announced that ANKTIVA is now commercially available in Saudi Arabia for bladder and lung cancer patients, achieving market entry within two months of a MENA partnership. This expansion follows the company's FY2025 revenue surge to $113 million from ANKTIVA, but it continues to operate at a net loss of $351 million with substantial doubt about its ability to continue as a going concern. Despite the positive portrayal, the timing coincides with an FDA warning letter from March 2026 over promotional claims, which could constrain U.S. growth and have global repercussions. The company's extreme customer concentration and reliance on external funding mean that any new revenue must quickly offset high cash burn to avoid further dilution. Investors should view this as a minor step in geographic diversification, with the key tests remaining sequential U.S. revenue growth and FDA remediation.

Implication

1. The availability of ANKTIVA in Saudi Arabia introduces a potential revenue stream that could support top-line growth in future quarters. 2. However, with operating cash burn exceeding $300 million annually, even successful international sales may not significantly reduce the need for external capital. 3. The ongoing FDA promotional warning letter creates uncertainty that could affect marketing strategies globally, including in new regions like Saudi Arabia. 4. Investors must monitor whether this expansion leads to tangible ex-U.S. revenue without increasing operational risks such as customer concentration. 5. Consequently, while the news aligns with the bull case for geographic diversification, it does not alter the near-term imperative for U.S. revenue momentum and regulatory compliance.

Thesis delta

The Saudi expansion is consistent with ImmunityBio's strategy to grow ex-U.S. revenue, but it does not shift the investment thesis, which hinges on sequential ANKTIVA net product revenue growth in the U.S. and containment of the FDA warning letter. Investors should continue to wait for clear evidence on these fronts before reassessing the WAIT rating.